Dianthus Therapeutics, Inc. (DNTH) Stock

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. (DNTH) stock trades at $76.78 with a market capitalization of $4.29B. The stock is valued at a negative price-to-earnings (P/E) ratio of -677.31, reflecting a net loss over the last twelve months, price-to-book of 4.21, price-to-sales of 2586.67. Over the past 52 weeks the stock has ranged between $32.22 and $117.88, and currently trades 34.9% below its 52-week high.

On profitability, Dianthus Therapeutics, Inc. generates a return on equity (ROE) of -3.51% (negative, reflecting a net loss), return on capital employed of -18.48%, an operating margin of -100.50%, a net profit margin of -8.48%.

Dianthus Therapeutics, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Dianthus Therapeutics, Inc. reported revenue of $0 rising to $2.0M. Compounded, revenue has grown —% a year over five years, -30.7% over three, -66.7% over the last twelve months. Net profit fell to $-162.0M.

The most recent net margin is -8.48%. On a trailing twelve-month basis to Jun '26, revenue is $1.0M and net profit $-30.0M.

Borrowings stand at $1.0M, cash from operations was $-129.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -25.7% over five years, and was -32.9% in the most recent year.

The share price itself has compounded at -13.2% a year over five years, 104.5% over three, 329.0% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Dianthus Therapeutics, Inc. (DNTH) — frequently asked questions